Intertape Polymer Group Inc. (ITP) EPS Estimated At $0.32; Quest Diagnostics (DGX) Shorts Down By 5.08%

April 17, 2018 - By Winifred Garcia

Quest Diagnostics Incorporated (NYSE:DGX) Logo

Quest Diagnostics Incorporated (NYSE:DGX) had a decrease of 5.08% in short interest. DGX’s SI was 5.10M shares in April as released by FINRA. Its down 5.08% from 5.38 million shares previously. With 872,400 avg volume, 6 days are for Quest Diagnostics Incorporated (NYSE:DGX)’s short sellers to cover DGX’s short positions. The SI to Quest Diagnostics Incorporated’s float is 3.76%. The stock decreased 0.49% or $0.4999 during the last trading session, reaching $100.7301. About 660,729 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has risen 1.33% since April 17, 2017 and is uptrending. It has underperformed by 10.22% the S&P500.

Analysts expect Intertape Polymer Group Inc. (TSE:ITP) to report $0.32 EPS on May, 8.They anticipate $0.03 EPS change or 10.34% from last quarter’s $0.29 EPS. T_ITP’s profit would be $18.82M giving it 15.63 P/E if the $0.32 EPS is correct. After having $0.25 EPS previously, Intertape Polymer Group Inc.’s analysts see 28.00% EPS growth. The stock increased 0.25% or $0.05 during the last trading session, reaching $20. About 41,173 shares traded. Intertape Polymer Group Inc. (TSE:ITP) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 21 analysts covering Quest Diagnostics (NYSE:DGX), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Quest Diagnostics had 69 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Quest Diagnostics Incorporated (NYSE:DGX) earned “Neutral” rating by Citigroup on Friday, September 9. RBC Capital Markets maintained the shares of DGX in report on Friday, January 29 with “Sector Perform” rating. FBR Capital maintained it with “Outperform” rating and $110 target in Wednesday, April 12 report. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, November 22. The firm has “Buy” rating given on Tuesday, February 13 by Credit Suisse. The stock of Quest Diagnostics Incorporated (NYSE:DGX) earned “Market Perform” rating by Wells Fargo on Friday, October 20. The stock has “Buy” rating by Mizuho on Wednesday, April 26. The stock of Quest Diagnostics Incorporated (NYSE:DGX) has “Hold” rating given on Friday, May 12 by Argus Research. The firm has “Hold” rating by Robert W. Baird given on Sunday, November 12. Zacks upgraded the stock to “Hold” rating in Tuesday, August 18 report.

Since January 2, 2018, it had 0 insider purchases, and 13 selling transactions for $30.90 million activity. $50,754 worth of Quest Diagnostics Incorporated (NYSE:DGX) was sold by Davis J. E. on Friday, February 23. Shares for $561,156 were sold by Doherty Catherine T. on Friday, March 2. Cohen Jon R sold $8.72M worth of Quest Diagnostics Incorporated (NYSE:DGX) on Thursday, March 8. PREVOZNIK MICHAEL E also sold $416,928 worth of Quest Diagnostics Incorporated (NYSE:DGX) on Friday, March 2. On Friday, February 23 the insider Klug Robert A sold $119,932. On Monday, January 29 RUSCKOWSKI STEPHEN H sold $11.43M worth of Quest Diagnostics Incorporated (NYSE:DGX) or 106,840 shares.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $13.68 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 18.31 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

Investors sentiment decreased to 0.92 in 2017 Q4. Its down 0.06, from 0.98 in 2017Q3. It worsened, as 52 investors sold Quest Diagnostics Incorporated shares while 192 reduced holdings. 67 funds opened positions while 158 raised stakes. 115.48 million shares or 1.22% less from 116.90 million shares in 2017Q3 were reported. Spirit Of America Management Corporation holds 0.05% or 4,500 shares. Amica Retiree Trust holds 0.08% in Quest Diagnostics Incorporated (NYSE:DGX) or 1,058 shares. Etrade Limited Com has 0.09% invested in Quest Diagnostics Incorporated (NYSE:DGX). Marshwinds Advisory accumulated 0.32% or 7,100 shares. The Wisconsin-based Dana Inv Advsr Inc has invested 0.2% in Quest Diagnostics Incorporated (NYSE:DGX). Sei reported 209,290 shares. Toronto Dominion Financial Bank holds 58,998 shares or 0.02% of its portfolio. Georgia-based Tnb has invested 0.09% in Quest Diagnostics Incorporated (NYSE:DGX). Strs Ohio reported 15,739 shares. 8,698 are held by Bb&T Securities Llc. Blair William Communications Il stated it has 4,337 shares or 0% of all its holdings. Mercer Cap Advisers invested in 1,076 shares. Bluecrest Management holds 0.03% or 10,523 shares in its portfolio. Susquehanna Group Incorporated Ltd Liability Partnership reported 0% in Quest Diagnostics Incorporated (NYSE:DGX). Baldwin Brothers Inc Ma reported 395 shares or 0.01% of all its holdings.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts